SURVYR

ROIV

Roivant Sciences
$36.54
+$0.49 (1.36%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-7%+25%+58%+90%+122%Oct 2025Oct 2026Apr 202652w high $41.8152w low $18.41
ROIVSPY
Wall St. Highest PT $53.05 (+45.2%) Wall St. Avg PT $43.48 (+19.0%)
$18$27$37$46$55POC $29Hi $53Avg $43
Underwater Drawdown %Max DD -20.2%Current -12.6%
0.0%-20.2%
Relative Strength vs SPY+80.7% vs SPYOutperforming
+127%0%-127%
1W
+$1.62 (4.64%)
1M
+$0.74 (2.07%)
3M
+$2.70 (7.98%)
6M
+$8.77 (31.58%)
YTD
+$14.84 (68.39%)
1Y
+$17.73 (94.26%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.46
1 = Strong Buy · 5 = Sell
Strong Buy969%
Buy215%
Hold215%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 21, 2026
Analyst price targets
Current price$36.54
Average target$48.91
+$12.37 (+33.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$41.00
Median$47.00
High$62.00
12-month Wall Street target range · as of Oct 21, 2026

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$18.41 – $41.81

What they do

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications. The company's lead program consists of mosliciguat.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
92nd percentile in sector
A
12-1 return: +82.9%
Percentile within its GICS sector across the S&P 1500.
Growth
2nd percentile in sector
F
Revenue growth (YoY): -33.5%
Percentile within its GICS sector across the S&P 1500.
Value
Not enough data yet
–
Forward E/P: – · EBITDA/EV: –
Percentile within its GICS sector across the S&P 1500.
Profitability
19th percentile in sector
D
Profit margin: +0.0% · Return on equity: -8.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Biotech, -13% from 52-week high, biotech, price-only entry, 12-1 momentum +129%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-27) it is outside the top 25.

Earnings & events

ROIV earningsNext report in 13 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Before the open
EPS consensus-$0.30
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.34est -$0.36+4.9%Above estimates
May 20, 2026-$0.32est -$0.35+9.3%Above estimates
Feb 6, 2026-$0.24est -$0.31+23.0%Above estimates
Nov 10, 2025-$0.28est -$0.30+9.3%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:08:01 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.360.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Roivant Sciences stock surges on positive uveitis trial data
Investing.com · Oct 21
Roivant Sciences (ROIV) files 8-K: Reg FD disclosure
SEC 8-K · Oct 21
Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run
Simply Wall St. · Oct 18

Research

New Highs Growth: rebalance of Sep 30, 2026Oct 22, 2026
Insider trades
Venker Eric
President & Immunovant CEO · 2026-10-20
Sell
$501.0K
Venker Eric
President & Immunovant CEO · 2026-10-20
Sell
$6.5M
Epperly Melissa B,
Director · 2026-10-01
Sell
$32.9K
Epperly Melissa B,
Director · 2026-10-01
Sell
$607.9K
Venker Eric
President & Immunovant CEO · 2026-09-30
Sell
$7.3M
Fitzgerald Meghan
Director · 2026-09-15
Sell
$16.2K
Fitzgerald Meghan
Director · 2026-09-15
Sell
$187.0K
Epperly Melissa B,
Director · 2026-09-15
Sell
$24.2K
Epperly Melissa B,
Director · 2026-09-15
Sell
$172.0K
Fitzgerald Meghan
Director · 2026-09-08
Sell
$798.0K
Venker Eric
President & Immunovant CEO · 2026-08-28
Sell
$1.2M
Venker Eric
President & Immunovant CEO · 2026-08-28
Sell
$5.9M

Stats refreshed 2026-10-27 18:08:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026